173 related articles for article (PubMed ID: 37781029)
1. CD36-BATF2\MYB Axis Predicts Anti-PD-1 Immunotherapy Response in Gastric Cancer.
Jiang Q; Chen Z; Meng F; Zhang H; Chen H; Xue J; Shen X; Liu T; Dong L; Zhang S; Xue R
Int J Biol Sci; 2023; 19(14):4476-4492. PubMed ID: 37781029
[TBL] [Abstract][Full Text] [Related]
2. Predicting response to immunotherapy in gastric cancer via multi-dimensional analyses of the tumour immune microenvironment.
Chen Y; Jia K; Sun Y; Zhang C; Li Y; Zhang L; Chen Z; Zhang J; Hu Y; Yuan J; Zhao X; Li Y; Gong J; Dong B; Zhang X; Li J; Shen L
Nat Commun; 2022 Aug; 13(1):4851. PubMed ID: 35982052
[TBL] [Abstract][Full Text] [Related]
3. The crosstalk between H. pylori virulence factors and the PD1:PD-L1 immune checkpoint inhibitors in progression to gastric cancer.
Aydın EM; Demir TD; Seymen N; Said SS; Oktem-Okullu S; Tiftikci A; Cicek B; Tokat F; Tozun N; Ince U; Sezerman U; Sayi-Yazgan A
Immunol Lett; 2021 Nov; 239():1-11. PubMed ID: 34363898
[TBL] [Abstract][Full Text] [Related]
4. Multidimensional immune profiling in Gastric Cancer Multiplex Immunohistochemistry Atlas from Peking University Cancer Hospital project informs PD-1/PD-L1 blockade efficacy.
Jia K; Chen Y; Xie Y; Chong X; Li Y; Wu Y; Yuan J; Li Y; Feng X; Hu Y; Sun Y; Gong J; Zhang X; Li J; Shen L
Eur J Cancer; 2023 Aug; 189():112931. PubMed ID: 37343324
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxic T-lymphocyte-associated protein 4 in gastric cancer: Prognosis and association with PD-L1 expression.
Pereira MA; de Castria TB; Ramos MFKP; Dias AR; Cardili L; de Moraes RDR; Zilberstein B; Nahas SC; Ribeiro U; de Mello ES
J Surg Oncol; 2021 Dec; 124(7):1040-1050. PubMed ID: 34255356
[TBL] [Abstract][Full Text] [Related]
6. The role of BATF2 deficiency in immune microenvironment rearrangement in cervical cancer - New biomarker benefiting from combination of radiotherapy and immunotherapy.
Zong Y; Chang Y; Huang K; Liu J; Zhao Y
Int Immunopharmacol; 2024 Jan; 126():111199. PubMed ID: 37995570
[TBL] [Abstract][Full Text] [Related]
7. Multiplex immunohistochemistry defines the tumor immune microenvironment and immunotherapeutic outcome in CLDN18.2-positive gastric cancer.
Jia K; Chen Y; Sun Y; Hu Y; Jiao L; Ma J; Yuan J; Qi C; Li Y; Gong J; Gao J; Zhang X; Li J; Zhang C; Shen L
BMC Med; 2022 Jul; 20(1):223. PubMed ID: 35811317
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Significance of PD-1, PD-L1 and CD8 Gene Expression Levels in Gastric Cancer.
Ito S; Masuda T; Noda M; Hu Q; Shimizu D; Kuroda Y; Eguchi H; Tobo T; Utsunomiya T; Mimori K
Oncology; 2020; 98(7):501-511. PubMed ID: 32380498
[TBL] [Abstract][Full Text] [Related]
9. MFSD2A potentiates gastric cancer response to anti-PD-1 immunotherapy by reprogramming the tumor microenvironment to activate T cell response.
Zhang B; Wang CM; Wu HX; Wang F; Chai YY; Hu Y; Wang BJ; Yu Z; Xia RH; Xu RH; Cao XT
Cancer Commun (Lond); 2023 Oct; 43(10):1097-1116. PubMed ID: 37539769
[TBL] [Abstract][Full Text] [Related]
10. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
[TBL] [Abstract][Full Text] [Related]
11. Immunoexpression of PD-L1, CD4+ and CD8+ cell infiltrates and tumor-infiltrating lymphocytes (TILs) in the microenvironment of actinic cheilitis and lower lip squamous cell carcinoma.
Souza VG; Santos DJS; Silva AG; Ribeiro RIMA; Loyola AM; Cardoso SV; Miranda CSS; Cardoso LPV
J Appl Oral Sci; 2022; 30():e20210344. PubMed ID: 35195152
[TBL] [Abstract][Full Text] [Related]
12. Predictive value of NLR, TILs (CD4+/CD8+) and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer.
Zurlo IV; Schino M; Strippoli A; Calegari MA; Cocomazzi A; Cassano A; Pozzo C; Di Salvatore M; Ricci R; Barone C; Bria E; Tortora G; Larocca LM; Basso M; Martini M
Cancer Immunol Immunother; 2022 Jan; 71(1):45-55. PubMed ID: 34009410
[TBL] [Abstract][Full Text] [Related]
13. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
14. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
15. Combination cancer immunotherapy targeting TNFR2 and PD-1/PD-L1 signaling reduces immunosuppressive effects in the microenvironment of pancreatic tumors.
Zhang X; Lao M; Xu J; Duan Y; Yang H; Li M; Ying H; He L; Sun K; Guo C; Chen W; Jiang H; Zhang X; Bai X; Liang T
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35260434
[TBL] [Abstract][Full Text] [Related]
16. Molecular heterogeneity of anti-PD-1/PD-L1 immunotherapy efficacy is correlated with tumor immune microenvironment in East Asian patients with non-small cell lung cancer.
Jin R; Liu C; Zheng S; Wang X; Feng X; Li H; Sun N; He J
Cancer Biol Med; 2020 Aug; 17(3):768-781. PubMed ID: 32944405
[No Abstract] [Full Text] [Related]
17. A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer.
Han Y; Liu SM; Jin R; Meng W; Wu YL; Li H
Front Immunol; 2023; 14():1178193. PubMed ID: 37492578
[TBL] [Abstract][Full Text] [Related]
18. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.
Ma J; Li J; He N; Qian M; Lu Y; Wang X; Wu K
J Transl Med; 2023 Feb; 21(1):73. PubMed ID: 36737759
[TBL] [Abstract][Full Text] [Related]
19. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis.
Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H
JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of ITGB1 expression as a predictor of the therapeutic effects of immune checkpoint inhibitors in gastric cancer.
Xu C; Xie XL; Kang N; Jiang HQ
BMC Gastroenterol; 2023 Sep; 23(1):298. PubMed ID: 37667169
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
